Daniel Lenihan
Overview
Explore the profile of Daniel Lenihan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
3043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soman P, Khouri M, Lenihan D, Reyentovich A, Sperry B, Sowalsky K, et al.
Future Cardiol
. 2025 Jan;
21(2):75-81.
PMID: 39878480
Introduction: The 6-minute walk test (6MWT) is used to assess submaximal exercise capacity in clinical trials. Conducting the 6MWT can be challenging when patients cannot visit the clinic due to...
2.
Khadke S, Kumar A, Bhatti A, Dani S, Al-Kindi S, Nasir K, et al.
J Card Fail
. 2024 Dec;
PMID: 39667523
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote weight loss and improve heart failure-related symptoms, quality of life, and functional capacity in patients with obesity and heart failure with preserved ejection...
3.
Kumar A, Khadke S, AlKindi S, Rajagopalan S, Nasir K, Kazi D, et al.
JACC Adv
. 2024 Oct;
3(8):101106.
PMID: 39444413
Background: Evidence regarding the effect of long-term exposure to particulate matter (PM) 2.5 and comorbid cancer and cardiovascular disease (CVD) mortality is limited. Objectives: In this study, the author report...
4.
Bloom M, Vo J, Rodgers J, Ferrari A, Nohria A, Deswal A, et al.
J Card Fail
. 2024 Oct;
31(2):415-455.
PMID: 39419165
Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at...
5.
Bloom M, Vo J, Rodgers J, Ferrari A, Nohria A, Deswal A, et al.
J Card Fail
. 2024 Oct;
31(2):456-463.
PMID: 39414560
No abstract available.
6.
Bloom M, Alvarez-Cardona J, Ganatra S, Barac A, Pusic I, Lenihan D, et al.
Cardiooncology
. 2024 Sep;
10(1):63.
PMID: 39342407
Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer...
7.
Keramida K, Farmakis D, Rakisheva A, Tocchetti C, Ameri P, Asteggiano R, et al.
Eur J Heart Fail
. 2024 Aug;
26(10):2077-2093.
PMID: 39193837
No abstract available.
8.
Tocchetti C, Farmakis D, Koop Y, Andres M, Couch L, Formisano L, et al.
Eur J Heart Fail
. 2024 Aug;
26(10):2055-2076.
PMID: 39087551
The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can...
9.
Tantawy M, Langaee T, Wang D, Rubinstein S, Cornell R, Lenihan D, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39063038
This study investigates the association between circulating microRNA (miRNA) expression and cardiovascular adverse events (CVAE) in multiple myeloma (MM) patients treated with a carfilzomib (CFZ)-based regimen. A cohort of 60...
10.
Shabnaz S, Nguyen T, Williams R, Rubinstein S, Garrett T, Tantawy M, et al.
Clin Transl Sci
. 2024 May;
17(5):e13828.
PMID: 38783568
As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to...